Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.31 USD | +0.30% | -3.41% | -11.27% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.27% | 481M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.73% | 21.97B | |
-4.73% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Goldman Sachs Adjusts UroGen Pharma's Price Target to $11 from $10, Maintains Neutral Rating